Immunotherapy, Radiotherapy, Rectal Cancer
Conditions
Brief summary
This is a open-label, single-arm study to investigate the safety and efficacy of consolidative chemotherapy with camrelizumab, an anti-PD-1 antibody drug following short course radiotherapy and subsequent surgical therapy in patients with locally advanced resectable rectal cancer.
Detailed description
Patients with locally advanced rectal cancer (cT3-4 or N+) are assigned to receive preoperative 5 × 5 Gy irradiation over 5 days with consolidation chemotherapy consisting two cycles of CAPOX chemotherapy and camrelizumab, an anti-PD-1 antibody drug for two cycles. Subsequent surgical therapy is performed to evaluate the safety and efficacy.
Interventions
DRUGCamrelizumab
Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients who personally provided written consent for participation in the study 2. Treatment-naive patients with rectal cancer, in whom the inferior margin of the tumor is at a distance of 10 cm or less from the AV before CRT 3. Primary rectal cancer histopathologically confirmed to be adenocarcinoma 4. Clinical stage of T3/T4 or N positive and M0,before CRT 5. Patients with the ECOG performance status of 0 or 1 at the time of enrollment 6. Women of childbearing potential who consent to practicing contraception during the period from giving informed consent to at least 23 weeks after the last dose of therapy 7. Male patients who consent to practicing contraception during the period from giving informed consent to at least 31 weeks after the last dose of the study drug
Exclusion criteria
1. Patients with recurrent rectal cancer or a history of pelvic radiation 2. Patients with a history of inflammatory bowel disease 3. Patients with a history of pneumonitis or interstitial lung disease 4. Patients with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease 5. Patients requiring treatment with systemic corticosteroids or immunosuppressants or who have received these treatments within 14 days before enrollment in the study 6. Patients with a history of thyroid dysfunction 7. Patients with a history or finding of cardiovascular risk 8. Patients who are positive for any of the following: HIV1 antibody, HIV2 antibody, HTLV1 antibody 9. Patients who are pregnant or lactating or who may be pregnant 10. Patients with significant unstable mental diseases or other medical diseases that may interfere with the safety of the subjects, obtaining informed consent, or compliance with the procedures for the clinical study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathological complete response | 1 year | Pathological complete response will be evaluated with American Joint Committee on Cancer (AJCC) Cancer Staging |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| margin-free (R0) resection rate | 1 years | margin-free (R0) resection rate |
| 3-year event-free survival rate | 3 years | 3-year event-free survival rate |
| safety, and quality of life | 1 year | Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. |
| 3-year overall survival rate | 3 year | 3-year overall survival rate |
Countries
China
Outcome results
None listed